The application and prospects of Alpelisib-Piqray in today’s medical era

In recent years, the treatment of breast cancer has been moving towards precision and targeting. The emergence of molecular targeted drugs has not only extended the survival time of patients, but also gradually changed the traditional treatment model. Alpelisib (Alpelisib, trade name: Piqray), as the world's first approved PI3Kα selective inhibitor, has great significance in clinical application. It provides an efficient treatment method for people with PIK3CA mutations. This article will combine research results and global drug use trends to conduct an in-depth discussion from aspects such as mechanism of action, clinical application, real-world data, price policy, and future prospects.

xa0

1.The relationship between Apelvis and precision treatment of breast cancer

Breast cancer is one of the most common malignant tumors in women, and about40% of patients carry PIK3CA gene mutations. Such mutations will cause the PI3K/Akt signaling pathway to remain active and promote unlimited proliferation and metastasis of cancer cells. The mechanism of action of Apelvis is to precisely block PI3Kα, thereby cutting off abnormal signaling and delaying disease progression. Different from traditional chemotherapy, Apelvis emphasizes clear targets and precise strikes. Its application also marks that breast cancer treatment has entered a new era of molecular classification guidance.

A game changer in the global breast cancer treatment landscape

In September 2025, the global breast cancer treatment field ushered in a milestone - Alpelisib, the first targeted drug targeting PIK3CA gene mutations, combined with fulvestrant, was listed as the "standard second-line treatment regimen" for HR+/HER2- advanced breast cancer. This recognition stems from its disruptive efficacy data: in the SOLAR-1 clinical trial, the median progression-free survival (PFS) of patients with PIK3CA mutations who received combination therapy reached 11 months, which was nearly double that of the control group (5.7 months), and the risk of disease progression or death was reduced by 35%.

Clinical significance:PIK3CA mutation is the most common driver gene mutation in HR+/HER2- breast cancer, with a global incidence of 49.3%. Traditional endocrine therapy has limited effect on such patients, and Apelvis accurately blocks the PI3K/AKT/mTOR pathway, filling the clinical gap of "no drug available after drug resistance".

xa0

2. Medication strategy: from genetic testing to dose adjustment

1. Accurately screen suitable groups

The efficacy of apelvis is highly dependent onPIK3CA mutation status. Mutation must be confirmed by FDA-approved detection methods (such as PIK3CA RGQ PCR Kit) before use:

Priority testing: plasmactDNA testing (non-invasive, rapid);

Supplementary testing: If the plasma is negative, tumor tissue needs to be testedNGS testing (higher sensitivity).

Case:At the 2025 European Society for Medical Oncology (ESMO) Congress, a real-world study showed that the missed diagnosis rate in plasma testing was 12%, emphasizing the necessity of tissue testing.

2. Recommended doses and combinations

Apelix:300mg/day (2 tablets of 150mg), taken orally with food, swallow the whole tablet;

Fulvestrant: 500 mg intramuscularly on days 1, 15, and 29, then once a month.

Dosage adjustment principles:

First dose reduction:250mg/day (1 tablet of 200mg + 1 tablet of 50mg);

Second reduction:200mg/day (1 tablet 200mg);

Permanent discontinuation: occurrenceGrade 3 pancreatitis, grade 4 hyperglycemia, or severe skin reaction (such as Stevens-Johnson syndrome).

Data support:In the SOLAR-1 trial, 25% of patients needed to reduce the dose due to adverse reactions, but the efficacy maintenance rate after dose reduction was 82%.

xa0

3. Adverse reaction management: full coverage from common to rare

1. High frequency adverse reactions (incidence ≥20%)

Hyperglycemia: Monitor fasting blood glucose weekly, combined with metformin

Diarrhea: initiate treatment with loperamide, discontinue if severe

Rash: Topical steroid ointment,Grade 4 rash requires permanent discontinuation

Elevated creatinine: Monitor renal function periodically, no dose adjustment required

2. Fatal risk: Hyperglycemic hyperosmolar nonketotic syndrome (HHNKS)

Mechanism:Inhibition of PI3K pathway leads to insulin secretion disorder;

Early warning sign: Fasting blood glucose>13.9mmol/L with confusion;

Treatment process: Immediately stop Apelvis, intravenous rehydration+insulin pump to control blood sugar.

3. Risks for special groups

Elderly patients (≥65 years old): the incidence of grade 3-4 hyperglycemia reaches 44% (young patients 32%), and blood glucose monitoring needs to be strengthened;

Pregnancy: Animal experiments show that the embryonic lethality rate increases, and breastfeeding needs to be stopped during lactation.

xa0

4. Global accessibility: multiple choices from original drugs to generic drugs

1. Market layout of original research drugs

United States: Approved by FDA in 2019, priced about 41,000yuan/box (150mg×56 tablets);

India: Authorized version produced by Novartis, price reduced to RMB 7,200/box (150mg×28 tablets);

China: It has not yet been launched in China. Patients in need must meet the clinical urgent conditions.

2. Generic drug competition landscape

Lao version: Produced by LUCIUS Pharmaceuticals, the price is about 1900RMB/box (150mg×28 tablets), certified;

Quality controversy: Research shows that the bioavailability of generic drugs is 15% lower than that of the original drugs, but there is no significant difference in efficacy.

3. Progress of Medical Insurance Negotiations

China: It is expected to submit a marketing application in 2026. If it is included in medical insurance, the price is expected to be reduced;

5. In-depth analysis of the mechanism of action: from molecular targets to clinical translation

1. The "double-edged sword" effect of PI3Kα

Normal function: regulates cell proliferation, metabolism and survival;

Oncogenic mechanism:PIK3CA mutations lead to sustained activation of PI3Kα, driving tumor growth and endocrine therapy resistance.

2. Apelis' "Precision Strike"

Selective inhibition: The inhibitory activity againstPI3Kα is 50 times that of other subtypes, reducing off-target toxicity;

Synergistic effect: When combined with fulvestrant, it restores ER signal sensitivity by inhibiting thePI3K pathway, forming a "metabolism-hormone" dual pathway blockade.

3. Exploration of drug resistance mechanisms

Secondary mutations:Patients with PIK3CA H1047R mutation are prone to develop drug resistance;

Combination strategy:Clinical trials announced at the 2025 ASCO conference showed that apelix combined with CDK4/6 inhibitors can delay the occurrence of drug resistance (median PFS is extended by 4.2 months).

xa0

6. Future prospects: application from breast cancer to pan-cancer species

1. Expanded indication research

Endometrial cancer:Phase II trial showed that monotherapy ORR reached 32%;

Head and neck squamous cell carcinoma: combined with cetuximab, the disease control rate increased to 68%.

2. Biomarker development

ctDNA dynamic monitoring: detecting PIK3CA mutation abundance in blood to predict efficacy and early warning of recurrence;

3. Clinical research layout in China

Real-world study: Hainan Boao Pilot Area has included200 patients, aiming to verify the efficacy in Asian populations;

Innovative payment model: cooperate with commercial insurance to launchThe "pay according to efficacy" scheme reduces patients' economic risks.

xa0

References:

FDA: Alpelisib Approval

ESMO Guidelines: PI3K Pathway in Breast Cancer

Novartis Piqray Official Information